Nutrition Disorders: Clinical Trials

783 trials for Nutrition Disorders, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

464 completed, 116 unknown, 58 recruiting, 43 terminated. 783 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 4783Completed 464, Unknown 116, Recruiting 58, Terminated 43, Not yet recruiting 40, Active not recruiting 30, Withdrawn 27, Enrolling by invitation 4, Suspended 1

Follow Nutrition Disorders: new trials by email Literature Review of Nutrition Disorders trials Research Report on Nutrition Disorders

Trials (filtered) newest first · largest first

All 783 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Community Active and Healthy Families Pragmatic Trial
Community Active and Healthy Families Intensive Health Behavior and Lifestyle Treatment - Child Obesity
Phase 4Not yet recruitingUniversity of Colorado, Denver4162028-01-012026-10-09
Patient-centred Intervention With Virtual Support for Obesity and Kidney Transplant Access
Semaglutide, Virtual Weight Management Coaching - Obesity, Chronic Kidney Disease
Phase 4Not yet recruitingKristin Clemens8802027-01-012026-10-05
SHAPE-ENDO: Pilot Randomized Trial of Multimodal Pre-Surgical Optimization Versus Standard Surgery in Patients With Obesity and Early-Stage Endometrial Cancer
GLP-1 Receptor Agonist, Levonorgestrel IUD (Lng-IUD), Oral Progestins - Endometrial Cancer, Endometrial Cancer Stage I
Phase 4Not yet recruitingHospital Universitari de Bellvitge802027-01-012026-06-10
Comparing Different Medication Regimens to Maintaining Weight Loss Among Adults With Obesity Using GLP-1s
GLP-1 dose reduction, non-GLP weight loss medication, Maintenance of GLP-1 dose - Obesity & Overweight, Cardiometabolic Health Indicators
Phase 4Not yet recruitingJing Luo602026-12-012026-11-03
GLP-1 Plus Lifestyle for Overall Wellness: Find Your Way Forward
Semaglutide - Obesity, Childhood
Phase 4Not yet recruitingUniversity of Minnesota10202026-11-152026-10-20
Effects of Maternal Multiple Micronutrient Supplementation During Lactation on Child Development in Ethiopia
UNIMMAP Multiple Micronutrient Supplement - Iodine Deficiency, Nutrition Poor
Phase 4Not yet recruitingBrown University6002026-11-012026-09-09
Metabolic Surgery for Atrial Fibrillation Elimination
Roux-en-Y Gastric Bypass or Sleeve Gastrectomy, Anti-Obesity Medication (AOM) treatment - Atrial Fibrillation, Obesity and Obesity-related Medical Conditions
Phase 4Not yet recruitingAli Aminian1002026-11-012026-04-17
Switching to Oral Weight Management Pharmacotherapy to Prevent Weight Regain After GLP-1 Therapy Discontinuation
Phentermine Pill, Orforglipron - Obesity
Phase 4Not yet recruitingMassachusetts General Hospital602026-11-012026-07-27
Mechanisms of Weight Loss: Tirzepatide vs Semaglutide
Tirzepatide, Semaglutide - Obesity (Disorder)
Phase 4RecruitingMcMaster University802026-10-312026-10-28
Effects of Tirzepatide on Esophagogastric Junction Mechanics, Reflux Burden, and Gastric Physiology in Adults With Obesity
Placebo, Tirzepatide - Obese Adults
Phase 4Not yet recruitingMayo Clinic302026-10-262026-10-26
Translational Health Research Into Vascular and Neurocognitive Effects of Weight Loss
semaglutide - Class I/II Obesity
Phase 4RecruitingAlain Dagher2402026-10-212026-10-26
Semaglutide in Youth With Autism Spectrum Disorder
Glucagon-like peptide-1 receptor agonist:Semaglutide, Lifestyle Management (LSM) Counseling - Autism Spectrum Disorder, Obesity
Phase 4RecruitingChildren's Hospital Medical Center, Cincinnati422026-10-182026-11-09
Resistance Training to Prevent Muscle Loss During Treatment With Tirzepatide
Dual GIP/GLP-1 Receptor Agonist Tirzepatide, Resistance Training - Obesity (BMI>30)
Phase 4RecruitingTechnical University of Munich1502026-10-072026-10-20
Tapered Versus Abrupt Discontinuation of Semaglutide After Treatment of Recurrent Weight Gain or Suboptimal Response Following Metabolic and Bariatric Surgery
Semaglutide weekly injection, Placebo - Morbid Obesity
Phase 4Not yet recruitingGeneral Committee of Teaching Hospitals and Institutes, Egypt1002026-10-012026-10-05
Semaglutide Given Before and After Conversion of Sleeve Gastrectomy to Roux-en-Y Gastric Bypass for Recurrent Weight Gain
Semaglutide weekly injection, Placebo - Morbid Obesity
Phase 4Not yet recruitingGeneral Committee of Teaching Hospitals and Institutes, Egypt1002026-10-012026-10-05
Semaglutide Before Primary Metabolic and Bariatric Surgery in Patients With BMI 60 kg/m² or Higher
Semaglutide weekly injection, Placebo - Morbid Obesity
Phase 4Not yet recruitingGeneral Committee of Teaching Hospitals and Institutes, Egypt1002026-10-012026-10-05
TRPTI Metabolic and GLP-1 Pharmacodynamic Study
TRPTI, Placebo - Overweight , Obesity
Phase 4Not yet recruitingRDC Clinical Pty Ltd202026-10-012026-09-30
Semaglutide 2.4 mg Once Weekly for Recurrent Weight Gain After Metabolic and Bariatric Surgery (RESURGE)
Semaglutide weekly injection, Placabo - Morbid Obesity
Phase 4Not yet recruitingGeneral Committee of Teaching Hospitals and Institutes, Egypt1042026-10-012026-10-05
GLP-1s in Hip and Knee Arthroplasty
GLP-1 Receptor Agonists + Behavioral modification, Behavioral + placebo - Arthritis, Obesity & Overweight
Phase 4Not yet recruitingNova Scotia Health Authority1002026-10-012026-08-10
Immediate Versus Criterion-triggered Semaglutide for Suboptimal Clinical Response One Year After Primary Metabolic and Bariatric Surgery
Semaglutide weekly injection, Placebo - Morbid Obesity
Phase 4Not yet recruitingGeneral Committee of Teaching Hospitals and Institutes, Egypt1002026-10-012026-10-05

Showing 20 of 783. Sign in to see all of them.

Narrower conditions

Obesity (499)  ·  Overweight (109)  ·  Vitamin D Deficiency (94)  ·  Diabetes Mellitus, Type 2 (73)  ·  Weight Loss (60)  ·  Malnutrition (58)  ·  Obesity, Morbid (57)  ·  Insulin Resistance (39)  ·  Diabetes Mellitus (34)  ·  Hypertension (33)  ·  Metabolic Syndrome (30)  ·  Pediatric Obesity (26)  ·  Cardiovascular Diseases (22)  ·  Polycystic Ovary Syndrome (16)  ·  Glucose Intolerance (15)

Broader conditions

Nutritional and Metabolic Diseases (783)  ·  Pathological Conditions, Signs and Symptoms (631)  ·  Signs and Symptoms (596)  ·  Overnutrition (586)  ·  Body Weight (572)  ·  Overweight (479)  ·  Metabolic Diseases (210)  ·  Glucose Metabolism Disorders (158)  ·  Endocrine System Diseases (157)  ·  Malnutrition (137)  ·  Deficiency Diseases (133)  ·  Avitaminosis (123)  ·  Urogenital Diseases (85)  ·  Diabetes Mellitus (78)

Interventions

Cholecalciferol (52)  ·  Liraglutide (49)  ·  Metformin (44)  ·  semaglutide (43)  ·  Vitamin D (37)  ·  Tirzepatide (29)  ·  Phentermine (16)  ·  Ergocalciferols (15)  ·  Sodium Chloride (15)  ·  Orlistat (12)  ·  Diet (11)  ·  Exenatide (11)  ·  Nutrition Assessment (11)  ·  Qsymia (11)  ·  Standard of Care (11)

Sponsors

Mayo Clinic (18)  ·  University Medical Centre Ljubljana (12)  ·  The Cleveland Clinic (7)  ·  Universitaire Ziekenhuizen KU Leuven (7)  ·  Yale University (7)  ·  General Committee of Teaching Hospitals and Institutes, Egypt (6)  ·  Hvidovre University Hospital (6)  ·  Texas Tech University Health Sciences Center (6)  ·  University of Colorado, Denver (6)  ·  University of Pennsylvania (6)  ·  Weill Medical College of Cornell University (6)  ·  Ain Shams University (5)  ·  Brigham and Women's Hospital (5)  ·  Columbia University (5)  ·  Radboud University Medical Center (5)

Countries

United States (254)  ·  China (44)  ·  Canada (43)  ·  Denmark (31)  ·  Italy (23)  ·  Netherlands (23)  ·  Mexico (22)  ·  France (20)  ·  Germany (20)  ·  United Kingdom (17)  ·  Brazil (16)  ·  Poland (16)  ·  Egypt (15)  ·  Belgium (12)  ·  India (11)

Top investigators

Ronald Hall, PharmD, MSCS (5)  ·  Andrej Janez, MD, PhD (4)  ·  Jan Tack (4)  ·  Ali Aminian, MD (3)  ·  Eda Vrtacnik Bokal, professor (3)  ·  Holly Wyatt, MD (3)  ·  James Hill, PhD (3)  ·  Samuel Klein, MD (3)  ·  Tania S Burgert, MD (3)  ·  Adrian Vella, MD (2)  ·  Alison Edelman, MD, MPH (2)  ·  Andrej Janez, MD PhD (2)

Results publications

PMID 33305842, PMID 15321413, PMID 16443140, PMID 18173431, PMID 19447599, PMID 19672175, PMID 20011857, PMID 20455872, PMID 21307769, PMID 21334503, PMID 21334504, PMID 22108086, PMID 22326199, PMID 22813360, PMID 23135692, PMID 23262963, PMID 23969793, PMID 23997449, PMID 24034832, PMID 24946047, PMID 25146109, PMID 25201313, PMID 25821536, PMID 25936783, PMID 26066773, PMID 26692415, PMID 26694495, PMID 27574464, PMID 27629425, PMID 27870737, PMID 28143456, PMID 35018442, PMID 8267196, PMID 10022643, PMID 10527182, PMID 11010931, PMID 11282917, PMID 11454256, PMID 11502778, PMID 11696118, PMID 11836290, PMID 12046553, PMID 12195709, PMID 12540646, PMID 12550060, PMID 12590412, PMID 12605179, PMID 12791627, PMID 14616423, PMID 14688154

NIH funding

2017 (5), 5UL1RR024982-02 (5), 2009 (3), 2015 (3), 2019 (3), 2008 (2), 2014 (2), 2018 (2), 2023 (2), 2025 (2), R01AG028739 (2), R01AT001103 (2), R01DK067071 (2), U54AG062319 (2), UL1TR000135 (2)